Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in Sjögren’s syndrome
Brendan Antiochos, Mariusz Matyszewski, Jungsan Sohn, Livia Casciola-Rosen, Antony Rosen
Brendan Antiochos, Mariusz Matyszewski, Jungsan Sohn, Livia Casciola-Rosen, Antony Rosen
View: Text | PDF
Research Article

IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in Sjögren’s syndrome

  • Text
  • PDF
Abstract

IFN-inducible protein 16 (IFI16) is an innate immune sensor that forms filamentous oligomers when activated by double-stranded DNA (dsDNA). Anti-IFI16 autoantibodies occur in patients with Sjögren’s syndrome (SS) and associate with severe phenotypic features. We undertook this study to determine whether the structural and functional properties of IFI16 play a role in its status as an SS autoantigen. IFI16 immunostaining in labial salivary glands (LSGs) yielded striking evidence of filamentous IFI16 structures in the cytoplasm of ductal epithelial cells, representing the first microscopic description of IFI16 oligomerization in human tissues, to our knowledge. Transfection of cultured epithelial cells with dsDNA triggered the formation of cytoplasmic IFI16 filaments with similar morphology to those observed in LSGs. We found that a majority of SS anti-IFI16 autoantibodies immunoprecipitate IFI16 more effectively in the oligomeric dsDNA-bound state. Epitopes in the C-terminus of IFI16 are accessible to antibodies in the DNA-bound oligomer and are preferentially targeted by SS sera. Furthermore, cytotoxic lymphocyte granule pathways (highly enriched in the SS gland) induce striking release of IFI16•dsDNA complexes from cultured cells. Our studies reveal that IFI16 is present in a filamentous state in the target tissue of SS and suggest that this property of DNA-induced filament formation contributes to its status as an autoantigen in SS. These studies highlight the role that tissue-specific modifications and immune effector pathways might play in the selection of autoantigens in rheumatic diseases.

Authors

Brendan Antiochos, Mariusz Matyszewski, Jungsan Sohn, Livia Casciola-Rosen, Antony Rosen

×

Figure 6

C-terminal specificity of SS sera with property of IFI16-DNA binding.

Options: View larger image (or click on image) Download as PowerPoint
C-terminal specificity of SS sera with property of IFI16-DNA binding.
(A...
(A) Cytoplasmic IFI16 filaments were induced in human salivary gland (HSG) cells and stained with commercial antibodies recognizing C-terminal (green) and N-terminal (red) epitopes. Both commercial antibodies recognize nuclear IFI16 (asterisk), but only the C-terminal antibody binds the cytoplasmic filament (arrow). (B) SS sera with or without the property of DNA-enhanced IFI16 immunoprecipitation were used to immunoprecipitate full-length IFI16 (FL) or an N-terminal fragment (IFI16ΔCT) lacking residues 597–729 at the C-terminus; data from Figure 5B specific to these 10 sera are shown. Commercial antibodies specific for the N-terminus (anti-NT) and C-terminus (anti-CT) were included. (C) Western blots were performed with anti-N terminal antibody. Blots were scanned by densitometry and the ratio of immunoprecipitated IFI16ΔCT/IFI16 FL in each was quantitated (Supplemental Table 2). Representative data obtained with 2 patient sera and the commercial antibodies is shown. Scale bar: 10 μM. Data are representative of results of 2 experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts